Highlights•Molnupiravir is a broad acting, oral antiviral versus SARS-CoV-2, flu, Ebola and
others.•Clinical development was greatly accelerated in response to the COVID19 …

Background: Randomized trial evidence suggests that some antiviral drugs are effective in
patients with COVID-19. However, the comparative effectiveness of antiviral drugs in …

Covid-19: What is the evidence for the antiviral molnupiravir? | The BMJ Skip to main content
Intended for healthcare professionals Access provided by Google Indexer Subscribe My …

Background: Information about the effectiveness of oral antivirals in preventing short-and
long-term COVID-19–related outcomes in the setting of Omicron variant transmission and …

The COVID-19 pandemic needs no introduction at present. Only a few treatments are
available for this disease, including remdesivir and favipiravir. Accordingly, the …

Background: The rapid worldwide spread of the Omicron variant of SARS-CoV-2 has
unleashed a new wave of COVID-19 outbreaks. The efficacy of molnupiravir, an approved …

The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) constitutes a major worldwide public health threat …

Molnupiravir is a β-d-N4-hydroxycytidine-5′-isopropyl ester (NHC) compound that exerts
antiviral activity against various RNA viruses such as influenza, SARS, and Ebola viruses …

Background Simnotrelvir is an oral 3-chymotrypsin–like protease inhibitor that has been
found to have in vitro activity against severe acute respiratory syndrome coronavirus 2 …

Background Little is known about the real-world effectiveness of oral antivirals against the
SARS-CoV-2 omicron (B. 1.1. 529) variant. We aimed to assess the clinical effectiveness of …